All In Biotech

Drug Trial Radar · NCT05134571

China Post-marketing Surveillance (PMS) Study of Aldurazyme®

A Phase 4, Single-arm, Open-label Safety and Efficacy Study of Aldurazyme® (Laronidase) as Enzyme Replacement Therapy in Participants With Mucopolysaccharidosis I (MPS I) in China

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Oct 28, 2021

Primary completion

Jul 26, 2023

Study completion Jul 26, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I. Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants. Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).

Conditions

  • Mucopolysaccharidosis I

Interventions

  • LaronidaseDrug

    Solution for injection; Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with adverse events (AEs)Time frame: Baseline to Week 27
  2. The incidence of Potentially clinically significant abnormality (PCSA) analyses for clinical laboratory, vital signs, and ECG parameters during the TE periodTime frame: Baseline to Week 27
  3. The percent change of uGAGsTime frame: Baseline to Week 26

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number :1560003

    Beijing, China

  • Investigational Site Number :1560002

    Beijing, China

  • Investigational Site Number :1560004

    Guangzhou, China

  • Investigational Site Number :1560006

    Hangzhou, China

  • Investigational Site Number :1560001

    Wuhan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.